Search clinical trials for: Murine CD19 CAR-T cells

Total 2465 results

Shenzhen Geno-Immune Medical Institute

Unknown

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Myeloma

China
Asclepius Technology Company Group (Suzhou) Co....

Unknown

Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor

Malignant Tumor

China
RenJi Hospital

Unknown

CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR

Advanced Glioma

China
Zhujiang Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Shenzhen Geno-Immune...

Recruiting

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

Myelodysplastic Syndromes | Leukemia, Acute Myelogenous (AML) | Leukemia, Acute Lymphocytic (ALL)

China
Shenzhen Fifth People's Hospital

Recruiting

An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects

CAR T-Cell Therapy

China
Wuhan Union Hospital, China
Wuhan Si'an Medical Technology Co., Ltd

Recruiting

Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma

China
Cellular Biomedicine Group Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

China
RenJi Hospital

Completed

Anti-GPC3 CAR T for Treating Patients With Advanced HCC

Hepatocellular Carcinoma

China
Peking University People's Hospital
Cellular Biomedicine Group Ltd.

Unknown

C-CAR011 Treatment in Subjects With ALL After HSCT

Acute Lymphoblastic Leukemia(ALL)

China
Affiliated Hospital to Academy of Military Medical...

Unknown

Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Lymphoma | Leukemia

China
Medical College of Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Central Nervous System Lymphoma | Mantle Cell Lymphoma (MCL) | Non Hodgkin Lymphoma (NHL)

United States
Medical College of Wisconsin

Not yet recruiting

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Multiple Myeloma
Instituto de Investigación Biomédica de Salamanca
Spanish Clinical Research Network - SCReN; Fundación Canaria de Investigación... and other collaborators

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)

B-cell Lymphoma Recurrent | Refractory B-Cell Lymphoma

Spain
Centre Henri Becquerel

Not yet recruiting

Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells (RT-CAR)

Diffuse Large B Cell Lymphoma

France
Beijing Friendship Hospital
Beijing Boren Hospital

Not yet recruiting

Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis

Langerhans Cell Histiocytosis

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd.

Recruiting

A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Refractory T-Cell Lymphoma | T Cell Lymphoma in Relapse

China
Beijing Tsinghua Chang Gung Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Suspended

GPC3-CAR-T Cells for the Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Xin Wang

Unknown

The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma

Relapsed or Refractory B-cell Lymphomas

China
Seattle Children's Hospital
The Evan Foundation; Ben Towne Center for Childhood Cancer Research

Active, not recruiting

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Neuroblastoma | Ganglioneuroblastoma

United States
Stephan Grupp MD PhD
Children's Hospital of Philadelphia; University of Pennsylvania; Tmunity Therapeutics

Recruiting

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (GPC2)

Refractory Neuroblastoma | High-risk Neuroblastoma | Relapsed Neuroblastoma

United States
Shenzhen University General Hospital

Recruiting

Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Shenzhen University General Hospital

Recruiting

Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

Advanced Pancreatic Carcinoma | Advanced Gastric Carcinoma

China
University College, London

Recruiting

CAR T Cells to Target GD2 for DMG (CARMIGO)

Diffuse Midline Glioma, H3 K27M-Mutant

United Kingdom
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Leukemia

China
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

Multiple Myeloma

China
Chinese PLA General Hospital

Recruiting

CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL

CD19+ Relapse/Refractory B-ALL

China
Shenzhen University General Hospital

Recruiting

CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer (CAR-T)

Advanced Pancreatic Carcinoma

China
University of Colorado, Denver

Recruiting

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Non-Hodgkin Lymphoma

United States
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Recruiting

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)

China
Marcela V. Maus, M.D.,Ph.D.

Completed

CAR-37 T Cells In Hematologic Malignancies

Lymphoma | Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Leukemia | Lymphoma, T-Cell | Hematologic Malignancy

United States
Beijing Immunochina Medical Science & Technology...

Not yet recruiting

Donor-derived CAR-T Cells in the Treatment of AML Patients

AML

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
University College, London

Not yet recruiting

Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma (MAGNETO)

Neuroblastoma
Shenzhen University General Hospital

Recruiting

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

T Lymphoblastic Leukemia/Lymphoma

China
Peking University

Not yet recruiting

Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma
Beijing Immunochina Medical Science & Technology...

Not yet recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Leukemia
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

Gastric Cancer | Pancreatic Cancer | Advanced Solid Tumors | Esophagogastric Junction Cancer

China
Shenzhen University General Hospital

Recruiting

B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Unknown

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Acute Myelocytic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation

AML

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Unknown

Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Non-hodgkin's Lymphoma

China
Cellular Biomedicine Group Ltd.
Shanghai Tongji Hospital, Tongji University School of Medicine

Unknown

Study of Safety and Efficacy of C-CAR011 in B-NHL Patients

Refractory or Relapsed Non-Hodgkin Lymphoma

China

Search clinical trials for: Murine CD19 CAR-T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations